Drug intelligence / Profile preview

GRI-0729

Development stage: Preclinical
Lead developer: GRI Bio
Modality: Small Molecules
Administration: Oral

Overview

GRI-0729 is a preclinical-stage type 2 Natural Killer T (NKT) cell agonist being developed by GRI Bio. The compound is designed to modulate the immune system by activating type 2 NKT cells, which play a regulatory role in balancing inflammatory immune responses. GRI Bio is focusing on the development of this asset for the treatment of various inflammatory, fibrotic, and autoimmune diseases. The program is part of a broader pipeline of NKT cell modulators that includes GRI-0621 (a type 1 NKT antagonist) and other type 2 NKT agonists like GRI-0124.

Beyond the preview

Go deeper on GRI-0729.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GRI-0729.

Explore the full profile